IMO at the beginning of August, JT had a meeting/call with the FDA...at that meeting, JT requested a broader label for Vascepa...this may have been a mistake...because the FDA, at that time, decided an Adcom would be necessary...JT may not have anticipated this turn of events and became upset, as evinced at the CC.
News 
Market Data 
Discover 
